A5048970892- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- RNA Interference and Gene Delivery
- CAR-T cell therapy research
- Virus-based gene therapy research
- Single-cell and spatial transcriptomics
- Advanced biosensing and bioanalysis techniques
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- Mycobacterium research and diagnosis
- Cytomegalovirus and herpesvirus research
- Electron Spin Resonance Studies
- Calcium signaling and nucleotide metabolism
- Complementary and Alternative Medicine Studies
- Food Safety and Hygiene
- Poisoning and overdose treatments
- Hepatocellular Carcinoma Treatment and Prognosis
Sidney Kimmel Comprehensive Cancer Center
2023-2024
Johns Hopkins University
2023-2024
University of Baltimore
2024
Johns Hopkins Medicine
2024
All India Institute of Medical Sciences Raipur
2023
All India Institute of Medical Sciences
2023
All India Institute of Medical Sciences Bhopal
2023
Columbia University Irving Medical Center
2018-2019
The Ohio State University
2017
Nationwide Children's Hospital
2017
Abstract Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity dual programmed cell death protein 1 (PD-1) lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy for these tumors. We report a phase Ib trial that evaluated neoadjuvant nivolumab (Arm A, n = 16) or nivolumab–relatlimab B, in combination chemoradiotherapy 32 patients resectable stage II/stage III...
Abstract Purpose: Although immunotherapy is the mainstay of therapy for advanced non–small cell lung cancer (NSCLC), robust biomarkers clinical response are lacking. The heterogeneity responses together with limited value radiographic assessments to timely and accurately predict therapeutic effect—especially in setting stable disease—calls development molecularly informed real-time minimally invasive approaches. In addition capturing tumor regression, liquid biopsies may be informative...
Mycobacterium tuberculosis is the causative agent of disease, which has developed a myriad exceptional features contributing to its survival within hostile environment host cell. Unique cell wall structure with high lipid content plays an imperative role in pathogenicity mycobacteria. Cell components MTB such as lipoarabinomannan and Trehalose dimycolate (cord factor) are virulent nature apart from virulence genes. Virulent effect these factors on cells reduces immunity. LAM been known...
Abstract Background: Liquid biopsies can inform treatment strategies by rapidly and accurately assessing tumor burden; with emerging data supporting the clinical utility of circulating cell-free DNA (ctDNA) as an early endpoint immunotherapy response. Methods: We performed targeted error-correction sequencing ctDNA (n=330) matched white blood cell (WBC) (n=109) from 109 patients advanced non-small lung cancer (NSCLC) who received immune checkpoint inhibitor monotherapy (n=79) or...
e15675 Background: Novel immunotherapies may be effective in patients with HCC; however, advanced liver disease are often excluded from clinical trials. The goal of our study was to evaluate the safety and efficacy nivolumab for HCC a real-world context, including among disease. Methods: We examined all cases initiated on off-study alone or combination locoregional therapy at institution 2/2017 7/2018. Our sample included 14 patients. report participant demographics, baseline function,...
Although immunotherapy is the mainstay of therapy for advanced non-small cell lung cancer (NSCLC), robust biomarkers clinical response are lacking. The heterogeneity responses together with limited value radiographic assessments to timely and accurately predict therapeutic effect -especially in setting stable disease-call development molecularly-informed real-time minimally invasive predictive biomarkers. In addition capturing tumor regression, liquid biopsies may be informative evaluating...